347 related articles for article (PubMed ID: 30153220)
1. Characterization of the Neuroendocrine Tumor Immune Microenvironment.
da Silva A; Bowden M; Zhang S; Masugi Y; Thorner AR; Herbert ZT; Zhou CW; Brais L; Chan JA; Hodi FS; Rodig S; Ogino S; Kulke MH
Pancreas; 2018 Oct; 47(9):1123-1129. PubMed ID: 30153220
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours.
Pinato DJ; Vallipuram A; Evans JS; Wong C; Zhang H; Brown M; Dina RE; Trivedi P; Akarca AU; Marafioti T; Mauri FA; Sharma R
Neuroendocrinology; 2021; 111(5):465-474. PubMed ID: 32097935
[TBL] [Abstract][Full Text] [Related]
3. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M
Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the immune landscape of small bowel neuroendocrine tumors.
Cives M; Strosberg J; Al Diffalha S; Coppola D
Endocr Relat Cancer; 2019 Jan; 26(1):119-130. PubMed ID: 30400003
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
Oktay E; Yalcin GD; Ekmekci S; Kahraman DS; Yalcin A; Degirmenci M; Dirican A; Altin Z; Ozdemir O; Surmeli Z; Diniz G; Ayhan S; Bulut G; Erdogan A; Uslu R
J BUON; 2019; 24(2):779-790. PubMed ID: 31128036
[TBL] [Abstract][Full Text] [Related]
7. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
10. Antitumor immune response is associated with favorable survival in GEP-NEN G3.
Rosery V; Reis H; Savvatakis K; Kowall B; Stuschke M; Paul A; Dechêne A; Yang J; Zhao B; Borgers A; Kasper S; Schuler M; Cheung PF; Siveke JT
Endocr Relat Cancer; 2021 Sep; 28(10):683-693. PubMed ID: 34472429
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
Ali AS; Langer SW; Federspiel B; Hjortland GO; Grønbæk H; Ladekarl M; Welin S; Weber Vestermark L; Arola J; Osterlund P; Knigge U; Sørbye H; Micke P; Grimelius L; Grönberg M; Tiensuu Janson E
PLoS One; 2020; 15(12):e0243900. PubMed ID: 33315908
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumours and their microenvironment.
de Hosson LD; Takkenkamp TJ; Kats-Ugurlu G; Bouma G; Bulthuis M; de Vries EGE; van Faassen M; Kema IP; Walenkamp AME
Cancer Immunol Immunother; 2020 Aug; 69(8):1449-1459. PubMed ID: 32270230
[TBL] [Abstract][Full Text] [Related]
13. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP
Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors.
Baretti M; Zhu Q; Zahurak M; Bhaijee F; Xu H; Engle EL; Kotte A; Pawlik TM; Anders RA; De Jesus-Acosta A
Pancreas; 2021 May-Jun 01; 50(5):719-726. PubMed ID: 34016898
[TBL] [Abstract][Full Text] [Related]
15. Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors.
Vesely C; Wong YNS; Childs A; Akarca AU; Dhami P; Vaikkinen H; Conde L; Herrero J; Ogunbiyi O; Gander A; Luong TV; Thirlwell C; Caplin M; Toumpanakis C; Peggs K; Quezada SA; Marafioti T; Meyer T
Clin Cancer Res; 2022 Jun; 28(12):2657-2668. PubMed ID: 35320356
[TBL] [Abstract][Full Text] [Related]
16. Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
Thota R; Gonzalez RS; Berlin J; Cardin DB; Shi C
Am J Clin Pathol; 2017 Sep; 148(3):208-214. PubMed ID: 28821192
[TBL] [Abstract][Full Text] [Related]
17. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA
Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
